Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-30T23:19:11.087Z Has data issue: false hasContentIssue false

Prolactin secretion in response to haloperidol challenge in delusional (psychotic) and non-delusional depression

Published online by Cambridge University Press:  16 April 2020

L Lykouras*
Affiliation:
University of Athens, Department of Psychiatry, Clinical Research Center of Affective Disorders, Eginition Hospital, Athens, Greece
M Markianos
Affiliation:
University of Athens, Department of Psychiatry, Clinical Research Center of Affective Disorders, Eginition Hospital, Athens, Greece
J Hatzimanolis
Affiliation:
University of Athens, Department of Psychiatry, Clinical Research Center of Affective Disorders, Eginition Hospital, Athens, Greece
P Oulis
Affiliation:
University of Athens, Department of Psychiatry, Clinical Research Center of Affective Disorders, Eginition Hospital, Athens, Greece
G.N Christodoulou
Affiliation:
University of Athens, Department of Psychiatry, Clinical Research Center of Affective Disorders, Eginition Hospital, Athens, Greece
*
*Correspondence and reprints: Department of Psychiatry, Eginition Hospital, 74 Vass. Sophias Ave., Athens 115 28, Greece. Email address: [email protected] (L. Lykouras).
Get access

Extract

Certain studies on measures related to central neurotransmitter activity have demonstrated that in delusional (psychotic) depression there is a dopaminergic dysregulation which distinguishes it from non-psychotic depression. A neuroendocrinologic method to check the degree of DA receptor responsivity is by measuring the prolactin responses to acute intramuscular administration of haloperidol. We studied this possibility by applying the haloperidol test in seven delusional and ten non-delusional depressed patients. All patients met DSM-IV criteria for a major depressive episode, single or recurrent, with or without psychotic features. After a three-week washout period, 5 mg of haloperidol were injected i.m. and blood samples were taken at 0, 30, 60, 90 and 120 minutes. In both trials, significant time effects were observed (elevated prolactin levels, F = 11.36, P = 0.000). However, the prolactin responses to haloperidol did not differ significantly between the two patient groups (F = 0.12, P = 0.97). These data do not show a difference in D2 receptor responsivity, at least at the hypothalamus-pituitary level, between psychotic and non-psychotic depression.

Type
Original article
Copyright
Copyright © 2001 Éditions scientifiques et médicales Elsevier SAS. All rights reserved

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aberg-Wistedt, AWistedt, BBertilsson, LHigher, CSF levels of HVA and 5-HIAA in delusional compared to nondelusional depression Arch Gen Psychiatry 1985; 42: 925–926CrossRefGoogle Scholar
Agren, HTerrenius, LHallucinations in patients with major depression: interactions between CSF monoaminergic and endorphinergic indices J Affect Disord 1985; 9: 25–34CrossRefGoogle ScholarPubMed
American Psychiatric Association Diagnostic and statistical manual of mental disorders 4th 1994 APA Washington DCGoogle Scholar
Devanand, DPBowers, MBHoffman, EJNelson, JCElevated plasma homovanillic acid in depressed females with melancholia and psychosis Psychiatr Res 1985; 15: 1–4CrossRefGoogle ScholarPubMed
First, MBSpitzer, RLGibbon, MWilliams, J.B.MStructured Clinical Interview for DSM-IV axis I disorders. Patient ed. (SCID-I/P, Version 2.0) 1996 New York State Psychiatric Institute, Biometrics Research Department New YorkGoogle Scholar
Gruen, PHSachar, EJLanger, GAlrman, NLeifer, MFrantz, A et al. Prolactin response to neuroleptics in normal and schizophrenic subjects Arch Gen Psychiatry 1978; 35: 108–116CrossRefGoogle ScholarPubMed
Hamilton, MA rating scale for depression J Neurol Neurosurg Psychiatry 1960; 23: 56–62CrossRefGoogle ScholarPubMed
Hays, SERubin, RTDifferential prolactin responses to haloperidol and TRH in normal adult men Psychoneuroendocrinology 1981; 6: 45–52CrossRefGoogle ScholarPubMed
Kolakowska, RBraddo, C.K.LWiles, DFranklin, MGelder, MNeuroendocrine tests during treatment with neuroleptic drugs. I: plasma prolactin response to haloperidol challenge Br J Psychiatry 1981; 131: 400–412CrossRefGoogle Scholar
Lykouras, LMarkianos, MHatzimanolis, JMalliaras, DStefanis, CBiogenic amine metabolites in delusional (psychotic) depression and melancholia subtypes of major depression Prog Neuro-Psychopharmacol Biol Psychiatry 1994; 18: 1261–1271CrossRefGoogle ScholarPubMed
Markianos, MBotsis, AHatzimanolis, JStefanis, CProlactin responses to im haloperidol in drug-naive and drug-experienced schizophrenic patients Eur Psychiatry 1994; 9: 91–94CrossRefGoogle Scholar
Mazure, CMBowers, MRHoffman, FMiller, KBNelson, JCPlasma catecholamine metabolites in subtypes of major depression Biol Psychiatry 1987; 22: 1469–1472CrossRefGoogle ScholarPubMed
Moor, KELookingland, KJDopaminergic neuronal systems in the hypothalamusBlood, FEKupfer, DJPsychopharmacology: the fourth generation of progress 1995 Raven Press New YorkGoogle Scholar
Rothschild, AJSchatzberg, AFLanglais, PJLervinger, JEMiller, MMCole, JOPsychotic and nonpsychotic depressions. I: comparisons of plasma catecholamines and cortizol measures Psychiatr Res 1985; 20: 143–153CrossRefGoogle Scholar
Schatzberg, AFRothschild, AJPsychotic (delusional) depression: should it be included as distinct syndrome in DSM-IV? Am J Psychiatry 1992; 149: 733–745Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.